CASE REPORT

Amitraz Poisoning; A case study

TEJAS PRAJAPATI¹, NIMESH PATEL², NASIM ZAMANI³, OMID MEHRPOUR⁴,⁵*

For author affiliations, see end of text.

Received April 11, 2012; Accepted May 28, 2012

This paper is available online at http://ijpt.iums.ac.ir

ABSTRACT

Amitraz, an insecticide/acaricide of the formamidine pesticides group, is a α₂ adrenergic agonist and of the amine chemical family generally used to control animal ectoparasites. Poisoning due to amitraz is rare and characterized by central nervous system and respiratory depression, bradycardia, hypotension, hypothermia, hyperglycemia, nausea and vomiting. Few cases of intoxications in human beings due to this pesticide have been published in the literature. However, a clear and specific treatment protocol does not exist and this makes the successful managements of this poisoning (presented in the case reports) a probable useful guide for clinical practitioners in other poison centers. Management of amitraz poisoning is still considered to be supportive and symptomatic. We present a case of amitraz poisoning who successfully managed by supportive treatments in a 20 years old female.

Keywords: Amitraz; Bradycardia; Miosis; Central nervous system

Amitraz, a triazapentadiene compound and a member of the amine chemical family is a formamidine pesticides used worldwide. It is used as an insecticide/acaricide to control animal ectoparasites [1-3]. Commercial formulations of amitraz generally contain 12.5-20% of the drug in organic solvents, especially xylene, which is itself used in paints, cleaners, and glues [4]. Amitraz is a α₂-adrenergic agonist stimulating α₂ adrenergic receptors in the central nervous system (CNS) and both α₁ and α₂ adrenergic receptors in the periphery. It also inhibits monoamine oxidase (MAO) enzyme activity and prostaglandin E₂ synthesis [5]. Poisoning occurs through oral, inhalational (the most potential), and dermal routes and is accompanied by numerous signs and symptoms varying from CNS depression (drowsiness, coma, and convulsion), to miosis, or rarely, mydriasis, respiratory depression, bradycardia, hypotension, hypertension, hypothermia or fever, hyperglycemia, polyuria, vomiting, decreased gastrointestinal motility, and intestinal distension [4]. Adverse reactions and side effects have been reported in animals exposed to the product; however, only few human intoxication cases have been reported in the literature. We present a young female patient with amitraz poisoning who was conservatively managed in intensive care unit (ICU) for 36 hours and experienced a complete recovery.

CASE STUDY

A 20-year-old female referred to L.G. Hospital in Ahmedabad, Gujarat, India after the ingestion of 2 to 3 full table spoons of amitraz chemical (10% solution) in a suicidal attempt. Her first symptoms had begun about one hour post ingestion and included nausea and dizziness, after which vomiting had ensued. Her family had immediately brought her to our center where gastric lavage with normal saline and administration of activated charcoal (1 g/kg) were performed. She was then admitted to ICU for further management.

At presentation, she was drowsy but followed verbal commands. Her blood pressure, pulse rate, respiratory rate, and temperature were 126/80 mmHg, 60/90 bpm, 24/min, and 36.8°C, respectively. Analysis of blood gases showed PaO₂ of 106.4, O₂ saturation of 96%, pH of 7.40, PCO₂ of 34.0, and HCO₃⁻ of 21.6. Other lab tests were as follow: blood urea nitrogen: 13 mg/dL; creatinine: 0.80 mg/dL; sodium: 138.9 mEq/L;
Amitraz Poisoning; A case study

Increased intake may lead to interestingly ve...thal alanine transaminase: We administered atropine to...ected in almost 20% of the patients are discharged without any organ dysfunction. This is similar to the results of Demirel et al.

REFERENCES


CURRENT AUTHOR ADDRESSES

Tejas Prajapati, Department of Forensic Medicine & Toxicology, AMC MET Medical College, L. G. Hospital, Ahmedabad, Gujarat, India.
Nimesh Patel, Consultant Physician, Sanjeevani Heart & Medical Hospital, Ahmedabad, Gujarat, India.
Nasim Zamani, Department of Clinical Toxicology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Omid Mehrpour, Addiction Research Center (ADRC), Mashhad University of Medical Sciences; Medical Toxicology and Drug Abuse Research Center (MTDRC), Pasdaran Avenue, Birjand University of Medical Sciences (BUMS), Birjand 9713643138, Iran. E-mail: omid.mehrpour@yahoo.com.au (Corresponding author)